Skip to main content
Top
Published in: BMC Medical Research Methodology 1/2020

Open Access 01-12-2020 | Research article

A systematic survey of randomised trials that stopped early for reasons of futility

Authors: S. D. Walter, H. Han, G. H. Guyatt, D. Bassler, N. Bhatnagar, V. Gloy, S. Schandelmaier, M. Briel

Published in: BMC Medical Research Methodology | Issue 1/2020

Login to get access

Abstract

Background

Randomised trial protocols may incorporate interim analyses, with the potential to stop the study for futility if early data show insufficient promise of a treatment benefit. Previously, we have shown that this approach will theoretically lead to mis-estimation of the treatment effect. We now wished to ascertain the importance of this phenomenon in practice.

Methods

We reviewed the methods and results in a set of trials that had stopped for futility, identified through an extensive literature search. We recorded clinical areas, interventions, study design, outcomes, trial setting, sponsorship, planned and actual treatment effects, sample sizes; power; and if there was a data safety monitoring board, or a published protocol. We identified: if interim analyses were pre-specified, and how many analyses actually occurred; what pre-specified criteria might define futility; if a futility analysis formed the basis for stopping; who made the decision to stop; and the conditional power of each study, i.e. the probability of statistically significant results if the study were to continue to its complete sample size.

Results

We identified 52 eligible trials, covering many clinical areas. Most trials had multiple centres, tested drugs, and 40% were industry sponsored. There were 75% where at least one interim analysis was planned a priori; a majority had only one interim analysis, typically with about half the target total sample size. A majority of trials did not pre-define a stopping rule, and a variety of reasons were given for stopping. Few studies calculated and reported low conditional power to justify the early stop. When conditional power could be calculated, it was typically low, especially under the current trend hypothesis. However, under the original design hypothesis, a few studies had relatively high conditional power. Data collection often continued after the interim analysis.

Conclusions

Although other factors will typically be involved, we conclude that, from the perspective of conditional power, stopping early for futility was probably reasonable in most cases, but documentation of the basis for stopping was often missing or vague. Interpretation of truncated trials would be enhanced by improved reporting of stopping protocols, and of their actual execution.
Appendix
Available only for authorised users
Literature
1.
go back to reference Walter SD, Han H, Briel M, Guyatt GH. Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility. Stat Med. 2017;36:1506–18.CrossRef Walter SD, Han H, Briel M, Guyatt GH. Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility. Stat Med. 2017;36:1506–18.CrossRef
2.
go back to reference Stegert M, Kasenda B, von Elm E, You JJ, Blümle A, Tomonaga Y, Saccilotto R, Amstutz A, Bengough T, Briel M. DISCO study group An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules. J Clin Epidemiol. 2015;69:152–60.CrossRef Stegert M, Kasenda B, von Elm E, You JJ, Blümle A, Tomonaga Y, Saccilotto R, Amstutz A, Bengough T, Briel M. DISCO study group An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules. J Clin Epidemiol. 2015;69:152–60.CrossRef
3.
go back to reference Briel M, Olu KK, von Elm E, et al. A systematic review of discontinued trials suggested that most reasons for recruitment failure were preventable. J Clin Epidemiol. 2016;80:8–15.CrossRef Briel M, Olu KK, von Elm E, et al. A systematic review of discontinued trials suggested that most reasons for recruitment failure were preventable. J Clin Epidemiol. 2016;80:8–15.CrossRef
4.
go back to reference Alturki R, Schandelmaier S, Olu KK, von Niederhäusern B, Agarwal A, Frei R, Bhatnagar N, von Elm E, Briel M. Premature trial discontinuation often not accurately reflected in registries: comparison of registry records with publications. J Clin Epidemiol. 2017;81:56–63.CrossRef Alturki R, Schandelmaier S, Olu KK, von Niederhäusern B, Agarwal A, Frei R, Bhatnagar N, von Elm E, Briel M. Premature trial discontinuation often not accurately reflected in registries: comparison of registry records with publications. J Clin Epidemiol. 2017;81:56–63.CrossRef
5.
go back to reference Kasenda B, von Elm E, You J, Blümle A, et al. Prevalence, characteristics, and publication of discontinued randomized trials. J Am Med Assoc. 2014;311:1045–51.CrossRef Kasenda B, von Elm E, You J, Blümle A, et al. Prevalence, characteristics, and publication of discontinued randomized trials. J Am Med Assoc. 2014;311:1045–51.CrossRef
6.
go back to reference Kasenda B, von Elm EB, You J, et al. Learning from failure--rationale and design for a study about discontinuation of randomized trials (DISCO study). BMC Med Res Methodol. 2012;12:131.CrossRef Kasenda B, von Elm EB, You J, et al. Learning from failure--rationale and design for a study about discontinuation of randomized trials (DISCO study). BMC Med Res Methodol. 2012;12:131.CrossRef
7.
go back to reference Freidlin B. In Futility Analysis. Methods and applications of statistics in clinical trials volume 1: chapter 12, Balakrishnan N. Wiley: Hoboken, New Jersey, 2014; 176. Freidlin B. In Futility Analysis. Methods and applications of statistics in clinical trials volume 1: chapter 12, Balakrishnan N. Wiley: Hoboken, New Jersey, 2014; 176.
8.
go back to reference Proschan MA, Lan KKG, Wittes JT. Statistical monitoring of clinical trials: a unified approach, vol. 63. New York: Springer; 2006. Proschan MA, Lan KKG, Wittes JT. Statistical monitoring of clinical trials: a unified approach, vol. 63. New York: Springer; 2006.
9.
go back to reference Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Boca Raton and London: Chapman and Hall/CRC; 2000. p. 206. Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Boca Raton and London: Chapman and Hall/CRC; 2000. p. 206.
10.
go back to reference Lachin JM. A review of methods for futility stopping based on conditional power. Stat Med. 2005;24:2747–64.CrossRef Lachin JM. A review of methods for futility stopping based on conditional power. Stat Med. 2005;24:2747–64.CrossRef
11.
go back to reference Rothwell JC, Julious SA, Cooper CL. A study of target effect sizes in randomised controlled trials published in the health technology assessment journal. Trials. 2018;19:544.CrossRef Rothwell JC, Julious SA, Cooper CL. A study of target effect sizes in randomised controlled trials published in the health technology assessment journal. Trials. 2018;19:544.CrossRef
12.
go back to reference Avery KNL, Williamson PR, et al. Informing efficient randomised controlled trials: exploration of challenges in developing progression criteria for internal pilot studies. BMJ Open. 2017;7(2):e013537.CrossRef Avery KNL, Williamson PR, et al. Informing efficient randomised controlled trials: exploration of challenges in developing progression criteria for internal pilot studies. BMJ Open. 2017;7(2):e013537.CrossRef
13.
go back to reference Sully BGO, Julious SA, Nicholl J. An investigation of the impact of futility analysis in publicly funded trials. Trials. 2014;15:61.CrossRef Sully BGO, Julious SA, Nicholl J. An investigation of the impact of futility analysis in publicly funded trials. Trials. 2014;15:61.CrossRef
14.
go back to reference Dimairo M, Coates E, Pallmann P, et al. Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design. BMC Med. 2018;16:210.CrossRef Dimairo M, Coates E, Pallmann P, et al. Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design. BMC Med. 2018;16:210.CrossRef
16.
go back to reference Hughes MD, Freedman LS, Pocock SJ. The impact of stopping rules on heterogeneity of results in overviews of clinical trials. Biometrics. 1992;48:41–53.CrossRef Hughes MD, Freedman LS, Pocock SJ. The impact of stopping rules on heterogeneity of results in overviews of clinical trials. Biometrics. 1992;48:41–53.CrossRef
17.
go back to reference Guyatt GH, Briel M, Glasziou P, Bassler D, Montori VM. Problems of stopping trials early. Br Med J. 2012;344:e3863.CrossRef Guyatt GH, Briel M, Glasziou P, Bassler D, Montori VM. Problems of stopping trials early. Br Med J. 2012;344:e3863.CrossRef
18.
go back to reference Briel M, Meade M, Mercat A. Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. J Am Med Assoc. 2010;303(9):865–73. Briel M, Meade M, Mercat A. Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. J Am Med Assoc. 2010;303(9):865–73.
19.
go back to reference Wang H, Rosner GL, Goodman SN. Quantifying over-estimation in early stopped clinical trials and the “freezing effect” on subsequent research. Clin Trials. 2016;13:621–31.CrossRef Wang H, Rosner GL, Goodman SN. Quantifying over-estimation in early stopped clinical trials and the “freezing effect” on subsequent research. Clin Trials. 2016;13:621–31.CrossRef
Metadata
Title
A systematic survey of randomised trials that stopped early for reasons of futility
Authors
S. D. Walter
H. Han
G. H. Guyatt
D. Bassler
N. Bhatnagar
V. Gloy
S. Schandelmaier
M. Briel
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Medical Research Methodology / Issue 1/2020
Electronic ISSN: 1471-2288
DOI
https://doi.org/10.1186/s12874-020-0899-1

Other articles of this Issue 1/2020

BMC Medical Research Methodology 1/2020 Go to the issue